Andre Watson

About

I am Founder and CEO of Ligandal, a biotechnology company that has developed LigandForge and LigandAI for the discovery of AI targeting peptides as the roadway to personalized and precision therapies. Learn more at Ligandal’s mission is to enable precision and personalized medicine on a global scale. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type. My formal background is in Biomedical Engineering with a focus on Biomaterials Science and gene delivery. I started Ligandal when I was 22 and moved to Silicon Valley to gain support for developing the next generation of medicine. I am an inventor on 80 pending patents (21 granted, 5 allowed, remaining pend

Experience

Education